Search | Page 22 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (UPCI 13-165)

    ... Associated Drug(s):  Azacitidine Phase:  ...

    Clinical Trial last updated 04/29/2016 - 10:26am.

  2. Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

    ... Alemtuzumab Azacitidine Fludarabine ...

    Clinical Trial last updated 05/02/2016 - 11:10am.

  3. Research Retrospective for AA&MDSIF 30th Anniversary - Dr. Mikkael Sekeres

    ... 2009 demonstrated that for the first time, an MDS drug, azacitidine , has provided a survival advantage. We have a rising number ...

    Interview last updated 05/08/2013 - 2:51pm.

  4. Dr. Matt Walter on Mentorship

    ... MDS patients with a combination of drugs, vosaroxin and azacitidine .  Vosaroxin has a different mechanism of action than azacitidine. It can cause DNA damage to MDS cells. We will determine whether a ...

    Interview last updated 07/20/2015 - 1:04pm.

  5. Clinical Trials Report for April 2014

    ... NCT02085408 The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care ... A Phase 3 evaluation of the Efficacy and Safety of oral Azacitidine plus best supportive care versus placebo and best supportive care ...

    Page last updated 04/18/2014 - 3:36pm.

  6. What MDS Patients Should Know About Clinical Trials

    ... with MDS. These are lenalidomide (Revlimid®), azacitidine (Vidaza®), and decitabine (Dacogen®). We use a few ... -- people with higher risk MDS -- received either azacitidine alone, azacitidine and lenalidomide, or azacitidine combined with ...

    Interview last updated 11/13/2015 - 11:12am.

  7. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... and applied it specifically to patients who were on azacitidine (Vidaza®). This is important because both the IPSS and IPSS-R ... be used to predict survival in patients who are treated with azacitidine, thus it is valid for a patient who is about to start azacitidine ...

    Interview last updated 02/07/2013 - 1:28pm.

  8. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... with the commonly used hypomethylating agents (HMA), azacitidine (Vidaza®), and decitabine (Dacogen®)? The ... the mechanisms of action is for the two HMA drugs.  Both 5-azacitidine and deoxy-azacitdine are thought to cause reversal of DNA ...

    Interview last updated 06/17/2014 - 9:15am.

  9. Interviews with the Experts Comorbidities: When Other Medical Conditions Affect MDS Treatment

    ... low blood counts that often occur when treatment with azacitidine (Vidaza®) is started, there could be serious complications, ... even more difficult to treat with standard therapies such as azacitidine (Vidaza®) or lenalidomide (Revlimid®). The more things that are ...

    Interview last updated 11/17/2014 - 9:31am.

  10. Aplastic Anemia and MDS Overlap Syndrome

    ... the standard of care should be hypomethylating agents, azacitidine (Vidaza®) and decitabine (Dacogen®), which of course ...

    Interview last updated 05/13/2015 - 8:37am.